Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae361 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Oncologist, 2025. Verfasst von Roma A Kankaria und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, United States. Hauptthemen laut MEDLINE: Melanoma, Budesonide, Hepatitis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oncology at Vanderbilt University Medical Center.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have advanced the treatment of metastatic melanoma. However, some patients develop ICI-associated toxicities like hepatitis (ie, immune-mediated hepatitis; IMH). Although these toxicities usually resolve with steroids, steroid-refractory events may occur, which may be a major source of morbidity and mortality without obviously defined treatment algorithms. Herein, we present 2 patients with metastatic melanoma who had IMH that was steroid-refractory and only partially mycophenolate-responsive, but fully resolved with budesonide. The case suggests that budesonide is a potential option to treat IMH that is refractory to standard treatments, but further investigation in a larger series is needed to identify the most optimal setting for budesonide use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, United States.
- Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Förderung
- Oncology at Vanderbilt University Medical Center
Zitieren
APA
Kankaria, R. A., & Johnson, D. B. (2025). Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review. The Oncologist. https://doi.org/10.1093/oncolo/oyae361
Vancouver
Kankaria RA, Johnson DB. Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review. The Oncologist. 2025. doi:10.1093/oncolo/oyae361
BibTeX
@article{Kankaria2025,
author = {Kankaria, Roma A and Johnson, Douglas B},
title = {Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae361}
}
EUVIMED